Bryan Wahl - 18 Mar 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: General Counsel
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 18 Mar 2025
Net transactions value: -$463,766
Form type: 4
Filing time: 20 Mar 2025, 21:49:13 UTC
Previous filing: 18 Mar 2025
Next filing: 09 Mar 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Sale	$154,655	-3,341	-5.4%	$46.29	58,057	18 Mar 2025	Direct	F1
transaction	TARS	Common Stock	Sale	$154,571	-3,261	-5.6%	$47.40	54,796	19 Mar 2025	Direct	F1
transaction	TARS	Common Stock	Sale	$154,539	-3,084	-5.6%	$50.11	51,712	20 Mar 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Content

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.